Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Melinta Therapeutics, Inc. for the treatment of bacterial acne.[1]

Radezolid
Skeletal formula of radezolid
Clinical data
Routes of
administration
Intravenous infusion, oral
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • N-{[(5S)-3-(2-fluoro-4′-{[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H23FN6O3
Molar mass438.463 g·mol−1
3D model (JSmol)
  • CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(c2)F)c3ccc(cc3)CNCc4cnn[nH]4

References

edit
  1. ^ Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.

Further reading

edit